Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | EGFR | P00533 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.59 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.59 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705596 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL17610618 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL25736023 | 0.90 | ALDH1A1 (0.82) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL10144267 | 0.83 | ALDH1A1 (0.71) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL13060204 | 0.82 | ALDH1A1 (0.74) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL25737631 | 0.81 | EGFR (1.00) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL28509763 | 0.80 | KMT2A (0.67) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL9539321 | 0.80 | KDM4E (0.71) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| SCHEMBL9539318 | 0.80 | KDM4E (0.71) | ALDH1A1EGFRMEN1KMT2AHPGD | |
| Tyrphostin 51 SCHEMBL241622 | 0.77 | EGFR (0.80) | ALDH1A1EGFRMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | claimed |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-30 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4578457-A1 | PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-3474849-B1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DIABETES | BROAD INST INC (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119768182-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-04 | — | — | CN | disclosed |
| EP-4517326-A2 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-03-05 | — | — | EP | disclosed |
| EP-3997103-B9 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-20220301733-A1 | Nuclear Material and Methods | FUSION ENERGY SOLUTIONS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11406709-B2 | Therapeutic and research application of PDCL3 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022150763-A1 | NANOPARTICLE-MEDIATED IMMUNE CELL MANUFACTURE AND USES THEREOF | THE GEORGE WASHINGTON UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20170274075-A1 | THERAPEUTIC AND RESEARCH APPLICATION OF PDCL3 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2016044219-A1 | THERAPEUTIC AND RESEARCH APPLICATION OF PDCL3 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | ALDH1A1 4237/4885EGFR 219/4885MEN1 2450/4885 |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ALDH1A1 3223/4885EGFR 402/4885MEN1 1139/4885 |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FAP, FIBP, FGF23 | ALDH1A1 3484/4885EGFR 804/4885MEN1 1171/4885 |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | ALDH1A1 1572/4885EGFR 2861/4885MEN1 4026/4885 |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FGF2, FRS2 | ALDH1A1 3983/4885EGFR 139/4885MEN1 2709/4885 |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | FIBP, FGF2, FRS2 | ALDH1A1 3983/4885EGFR 139/4885MEN1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.